Showing results (571-580 of 579) with videos related to
Sort By:
Pageof 58
You have reached the last page of results.This site can display upto 579 results.
Dermatology and Therapy|May 18, 2026
Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical TrialChao Wu, Xuping Niu, Xiaohua Wang, et al.Cancer Cell|March 19, 2020
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 AxisHong Liu, Xinwei Kuang, Yongchang Zhang, et al.Journal of Medical Internet Research|March 17, 2023
Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and ApplicationKai Huang, Xian Wu, Yixin Li, et al.Chinese Medical Journal|September 8, 2025
Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trialKun Huang, Songmei Geng, Xiaohua Tao, et al.Dermatitis : Contact, Atopic, Occupational, Drug|July 25, 2025
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic DermatitisYan Zhao, Cheng Zhou, Xiaoyong Man, et al.Phenomics (Cham, Switzerland)|October 14, 2024
Expert Consensus on Big Data Collection of Skin and Appendage Disease Phenotypes in ChineseShuang Zhao, Zhongling Luo, Ying Wang, et al.The British Journal of Dermatology|February 17, 2024
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Congjun Jiang, Guoqiang Zhang, et al.Nature Communications|January 25, 2022
Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variantBaisheng Li, Aiping Deng, Kuibiao Li, et al.Cell|May 4, 2020
Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, ChinaJing Lu, Louis du Plessis, Zhe Liu, et al.Pageof 58